The event highlighted a shift from development to commercialization, with Flora Sync LF5 and DARE to PLAY launching in 2024, backed by strong provider ties and a digital health platform. Key clinical milestones for Ovaprene and DARE-HPV are due in 2025, and a menopause product is targeted for 2027. Growth is underpinned by non-dilutive funding and a de-risked, evidence-based strategy.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.